- Report
- May 2025
- 100 Pages
Global
From €5211EUR$5,950USD£4,523GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- September 2025
- 250 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Report
- March 2025
- 200 Pages
Global
From €3932EUR$4,490USD£3,413GBP
- Clinical Trials
- April 2025
- 60 Pages
Global
From €1752EUR$2,000USD£1,520GBP
- Report
- June 2025
- 400 Pages
Global
From €4334EUR$4,949USD£3,762GBP
- Report
- April 2025
- 205 Pages
Global
From €4375EUR$4,995USD£3,797GBP
- Report
- September 2025
- 101 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- August 2025
- 105 Pages
Global
From €3500EUR$4,281USD£3,144GBP
- Report
- August 2024
- 180 Pages
Global
From €2006EUR$2,290USD£1,741GBP
- Report
- October 2023
- 145 Pages
Global
From €2759EUR$3,150USD£2,395GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €3284EUR$3,750USD£2,851GBP
- Report
- March 2024
- 397 Pages
Global
From €6963EUR$7,950USD£6,043GBP
- Drug Pipelines
- July 2023
- 30 Pages
Global
From €2409EUR$2,750USD£2,090GBP
- Drug Pipelines
- January 2023
- 30 Pages
United States
From €2409EUR$2,750USD£2,090GBP
- Report
- August 2022
- 30 Pages
Global
From €2846EUR$3,250USD£2,471GBP
- Report
- April 2023
- 120 Pages
Global
From €4160EUR$4,750USD£3,611GBP
- Report
- May 2024
- 128 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- May 2024
- 140 Pages
Global
From €3502EUR$3,999USD£3,040GBP
- Report
- January 2025
- 91 Pages
Global
From €3500EUR$4,281USD£3,144GBP

Cariprazine is a medication used to treat mental disorders such as schizophrenia and bipolar disorder. It is a dopamine receptor partial agonist, meaning it binds to dopamine receptors in the brain and activates them to a lesser degree than dopamine itself. Cariprazine is thought to work by restoring the balance of certain natural substances in the brain, such as dopamine and serotonin. It is available in both oral and injectable forms.
Cariprazine is generally well-tolerated and has fewer side effects than other antipsychotic medications. Common side effects include nausea, headache, insomnia, and restlessness. It is important to note that cariprazine can cause serious side effects, such as an increased risk of death in elderly people with dementia-related psychosis.
Cariprazine is a relatively new medication and is not yet widely available. It is currently approved for use in the United States, Canada, and several European countries.
Some companies in the Cariprazine market include Gedeon Richter, Allergan, and Sunovion Pharmaceuticals. Show Less Read more